{"id":20264,"date":"2024-07-07T08:26:59","date_gmt":"2024-07-07T05:26:59","guid":{"rendered":"https:\/\/www.erotic-africa.com\/?p=20264"},"modified":"2024-07-08T08:27:25","modified_gmt":"2024-07-08T05:27:25","slug":"new-bi-annual-prophylaxis-hiv-trial-is-100pc-effective-against-infection","status":"publish","type":"post","link":"https:\/\/www.erotic-africa.com\/fr\/new-bi-annual-prophylaxis-hiv-trial-is-100pc-effective-against-infection\/","title":{"rendered":"Un nouvel essai semestriel sur la prophylaxie du VIH est efficace \u00e0 100 % contre l\u2019infection"},"content":{"rendered":"Reading Time: <\/span> 6<\/span> minutes<\/span><\/span>
\n

A significant trial conducted in Uganda and South Africa<\/a> has shown that administering a new PrEP(pre-exposure prophylaxis) via bi-annual injections ensures complete protection against HIV infection for young women.<\/p>\n

The trial compared the efficacy of Lenacapavir injection administered every six months with two existing daily oral PrEP medications. Lenacapavir disrupts the HIV\u00a0 caspid is vital for viral replication and is subjected subcutaneously. Gilead Sciences sponsored the controlled trial with 5000 participants across three sites in Uganda and 25 sites based in South Africa.<\/p>\n

The objectives were to assess the effectiveness and safety of lenacapavir compared to Truvada (F\/TDF) and Descovy (F\/TAF). The trial’s focus on women aged 16 to 25 was significant since this demographic faces the highest risk of new HIV infections in Southern and Eastern Africa. Truvada has been challenging for several young women due to various social and structural factors. The results of the trial mark a vital breakthrough in HIV prevention efforts.<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

The trial also evaluated the effectiveness of F\\TAF to F\\TDF. The former boasts superior pharmacokinetic properties compared to the latter referring to how the drug moves into, through and out of the body. It is currently used by men and transgender women in high-income countries.<\/p>\n

The trial employed a three-arm design where young women were assigned in a 2:2:1 ratio C (Len LA: F\/TAF oral: F\/TDF oral) in a double-blinded manner. This ensured that the participants and researchers were unaware of the treatment the participants received until the trial ended.<\/p>\n

In Eastern and Southern Africa, young women bear the highest burden of new HIV infections. They struggle to adhere to daily PrEP routines due to challenges including social and structural.<\/p>\n

Lenacapavir demonstrated a 100% prevention rate since during the trial phases none of the 2,134 women who received the vaccine contracted HIV. In comparison, of those who took Truvada, 16 out of 1068 women became infected, while 39 out of 2,136 who received Descovy contracted HIV.<\/p>\n

Based on the findings an independent review by the data safety monitoring board recommended quitting the blinded phase of the trial. This board had expert committee members appointed at the outset of the clinical trial, and reviewed unblinded data to monitor safety and progress. Their role includes ensuring that trials are discontinued if there is harm and clear benefit observed in one treatment arm over others.<\/p>\n

\n

Page Contents<\/p>\n